Teva Pharmaceuticals USA
Clinical trials sponsored by Teva Pharmaceuticals USA, explained in plain language.
US subsidiary of Teva, a global generic and specialty pharmaceutical company.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Generic psoriasis cream could offer cheaper alternative to VTAMA®
Disease control CompletedThis study tested whether a generic tapinarof cream works as well as the brand-name VTAMA® cream for adults with plaque psoriasis. 560 participants used either the generic cream, the brand-name cream, or a placebo for 12 weeks. The goal was to see if the generic version is equall…
Phase 3 • Sponsor: Teva Pharmaceuticals USA • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New biosimilar aims to tame stubborn hives at lower cost
Disease control CompletedThis completed Phase 3 trial tested whether TEV-45779, a biosimilar of the drug omalizumab (XOLAIR), works as well as the original for people with chronic hives that don't improve with antihistamines. 608 participants received either the biosimilar or XOLAIR. The main goal was to…
Phase 3 • Sponsor: Teva Pharmaceuticals USA • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC